Market revenue in 2023 | USD 758.5 million |
Market revenue in 2030 | USD 14,484.8 million |
Growth rate | 52.4% (CAGR from 2023 to 2030) |
Largest segment | Cancer |
Fastest growing segment | Cancer |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inflammatory & Autoimmune Disorders, Cancer |
Key market players worldwide | Amgen Inc, Roche Holding AG, Genentech, Akeso Inc Ordinary Shares, Janssen Pharmaceuticals, Taisho Pharmaceutical Holdings Co Ltd ADR, Immunocore Holdings PLC ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bispecific antibodies market will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 11.06% in 2023. Horizon Databook has segmented the Europe bispecific antibodies market based on inflammatory & autoimmune disorders, cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe bispecific antibodies market , including forecasts for subscribers. This continent databook contains high-level insights into Europe bispecific antibodies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account